Isomorphic Labs Eyes $40 Billion Valuation in Funding Talks: Alphabet's AI Drug-Discovery Spinout Hasn't Dosed a Single Patient

Bloomberg reported on Oct 8 that Isomorphic Labs — Alphabet's DeepMind spinout for AI drug discovery — is in early funding talks at a $40B valuation (potentially $50B). Eli Lilly and Novartis partnerships worth up to $3B underpin the ask. The company has yet to dose a single patient.

Bloomberg reported on October 8 that Isomorphic Labs is in early funding talks at a valuation of at least $40 billion, with the round potentially reaching as much as $50 billion — roughly double the company’s last private mark. The talks are preliminary; no deal has been finalized. The investor demand story is the headline, but the underline is what Isomorphic is actually selling: a drug-discovery platform that has signed up to $3 billion in partnership value with Eli Lilly and Novartis and has not yet dosed a single patient. (Bloomberg via Yahoo Finance, CryptoBriefing)

The framing matters. The last time Alphabet had a healthcare spinout raise at this scale, the unit had shipped something measurable. Isomorphic has shipped two things: a working pipeline of partnered programs and a deeper reason to believe the platform — but no clinical data yet.

What’s actually in the round

Per Bloomberg’s Oct 8 report, citing people familiar with the matter:

  • Floor valuation: $40 billion. Higher-end scenario: $50 billion.
  • Round type: external funding, with Alphabet retaining majority control.
  • Stage: early talks. No lead investor disclosed. No closing date.

Isomorphic’s last priced round was a $600M first external round in April 2024 (Thrive Capital, Alphabet), at a reported valuation of around $1.8–2.0B. The Bloomberg story implies a 20–28x markup in 30 months if the $40B floor closes — or a 25–28x markup if the $50B ceiling does. (IntuitionLabs, Bloomberg via Yahoo Finance)

That markup is bigger than the comparable AI-infrastructure 2024–2025 rounds (xAI’s Series B at ~5x markup, Anthropic’s at ~3x) and sits in the same range as the leading AI-drug-discovery peers. The implied pricing is the AI-platform premium, not the AI-infrastructure premium.

Why now: Eli Lilly, Novartis, and the $3B partnership book

The Isomorphic pitch is not “we built AlphaFold.” It’s “we built the AI drug-discovery engine on top of AlphaFold, and two top-5 pharma partners are paying us to use it.”

The original deal structure, signed in 2024:

  • Eli Lilly: Up to $45M upfront per program, plus tiered royalties and milestone payments; multi-target research collaboration.
  • Novartis: Up to $37.5M upfront per program, plus tiered royalties and milestone payments; multi-target research collaboration. Expanded in February 2025 with the initial scope focused on small-molecule discovery.
  • Total potential value: nearly $3 billion, excluding royalties from any drugs that reach the market. (Isomorphic Labs, Isomorphic Labs partnerships)

The structure is what’s interesting. Each program has a per-target upfront (low tens of millions), a multi-year research commitment, and a milestone-plus-royalty tail. Pharma pays for the AI platform to identify and optimize candidates, then pays again if any candidate advances to clinical trials and commercialization.

What Isomorphic actually built

The technology is twofold:

  1. AlphaFold 3 (released May 2024, after Isomorphic was already operating independently): Predicts the 3D structure of proteins, DNA, RNA, ligands, and ions — the molecular interactions that drive drug binding. The academic access model makes AlphaFold 3 free for non-commercial use; Isomorphic has commercial rights to integrate the predictions into its drug-discovery pipeline.
  2. IsoDDE (Isomorphic Drug Design Engine): The integrated platform combining AlphaFold-style structural prediction, generative chemistry, and active-learning loops. Pharma partners run their targets through IsoDDE; Isomorphic proposes and optimizes candidate molecules. (Isomorphic Labs — How We Work)

The “no patient dosed yet” line from CryptoBriefing is the one that needs framing. The Isomorphic pipeline has been operating for two years under the Lilly and Novartis deals; programs typically run 3–5 years from target nomination to IND-enabling studies before first-in-human trials. A platform with two-year-old pharma deals shouldn’t have a dosed patient yet — that’s not a red flag, that’s the standard timeline.

The bigger question is whether the platform has produced candidates that moved forward enough for the pharma partners to expand the deals. The Novartis expansion in February 2025 is the only public signal, and it’s the data point that supports the $40B valuation ask.

How this fits the AI drug-discovery landscape

The AI-drug-discovery space has consolidated around a handful of platforms with credible pharma partnerships. Isomorphic is one of them. Others:

Company Backing Pharma partnerships Clinical-stage candidates
Isomorphic Labs Alphabet (Google DeepMind spinout) Eli Lilly + Novartis (up to $3B) None disclosed
Insilico Medicine Sequoia, Baidu, Qiming Sanofi, Fosun, others Multiple INDs filed; one Phase 1 candidate (INS018_055 for IPF)
Recursion Pharmaceuticals Exscientia merger (2024) Roche/Genentech, Bayer Phase 1/2 pipeline
Exscientia Recursion merger (2024) Sanofi, BMS, others Multiple Phase 1 candidates

The pattern that matters: Insilico, Recursion, and Exscientia all have dosed patients. Isomorphic has partnerships of comparable scale but is earlier-stage on the clinical axis. The $40B ask is a bet that the platform premium and the Alphabet technical moat justify being priced ahead of the clinical timeline.

What this means in practice

For investors reading the Bloomberg story:

  • The $40B floor is an early-talk number, not a confirmed valuation. CryptoBriefing and Yahoo Finance both note the deal isn’t done. Expect the final number to settle somewhere in the $40–50B band, with closing in late 2026 or early 2027.
  • The round structure matters more than the headline number. If Alphabet retains majority control, the dilution for new investors is bounded; if Alphabet is selling down, the implications change. Bloomberg hasn’t disclosed the structure yet.
  • The Lilly/Novartis partnership book is the durable asset. Up to $3B in potential value is real revenue potential, not paper valuation. If both deals expand further, the round starts to look cheap at $40B.

For the broader AI-pharma space:

  • AI-drug-discovery has crossed the credibility threshold. A 20–28x markup in 30 months on a pre-clinical platform is not what investors pay for vaporware. It’s what they pay when they believe the platform will materially shorten the drug-discovery timeline.
  • The next twelve months are the test. If Isomorphic advances a partnered candidate to IND-enabling studies in 2026–2027, the $40B–$50B valuation looks prescient. If the partners quietly deprioritize programs, the round becomes a benchmark the next AI-pharma deal gets measured against — and probably marked down.

What to verify when this closes:

  • The closing valuation. Bloomberg’s “at least $40B” is a floor. The actual close will be a specific number; watch for the press release.
  • Lead investor identity. If Thrive Capital, Greenoaks, or a sovereign wealth fund leads, the round signals tech-platform capital. If a pharma corporate-VC leads, the round signals pharma-strategic alignment.
  • Alphabet’s ownership post-close. Majority retention means the round is growth capital, not equity transfer. Selling down means Alphabet is taking some chips off the table.
  • Pipeline disclosures. Has Isomorphic disclosed any IND-enabling studies or expanded collaborations since the Novartis February 2025 expansion? That’s the next material event.

Sources